Author + information
- Kesavan Sankaramangalam,
- Kinjal Banerjee,
- Brandon Jones,
- Krishna Kandregula,
- Yash Jobanputra,
- Lars Svensson and
- Samir Kapadia
Background: The impact of Coronary artery disease (CAD) on the outcome after Transcatheter Aortic Valve Replacement (TAVR) is not understood well. Finding an optimum revascularization strategy for the TAVR patients who have concomitant CAD is also an ongoing debate. We sought to evaluate the outcomes in patients with active CAD undergoing TAVR.
Methods: TAVR studies published between 2002 and October 2016 were reviewed. Out of the initial 1104 citations, 11 studies (7067 patients) reporting outcomes in patients with significant coronary lesions at the time of TAVR were included. Meta-analysis using pooled estimates was conducted.
Results: Out of the total 7067 patients who underwent TAVR, 3417 (48.35 %) had concomitant CAD. All-cause 30 day and 1 year mortality was 7.37% & 20.43% in patients with CAD and that for the patients without CAD were 6.67% & 14.95% respectively. Meta-analysis showed no significant difference between patients with or without concomitant CAD for 30 day mortality [Odds ratio (OR) – 1.05; Confidence interval (CI) – 0.74-1.49, p=0.318], but 1 year mortality was higher in the patients with CAD (OR: 1.38; CI: 1.09-1.74, p <0.001).
Conclusions: Even though the Co-existing active CAD does not have an impact on the 30 day mortality of TAVR patients, it does have a negative impact on the long term outcome after TAVR. Further studies need to be done to find out how the revascularization strategies will impact the outcome of the patients after TAVR.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Interventional Cardiology: TAVR 2
Abstract Category: 17. Interventional Cardiology: Aortic Valve Disease
Presentation Number: 1195-188
- 2017 American College of Cardiology Foundation